Coronavirus: A “Mild” Virus Turned Deadly Infection

Rizwan Ali Naqvi¹, Muhammad Faheem Mushtaq², Nazish Ali Mian³, Muhammad Adnan Khan⁴*, Atta-ur-Rahman⁵, Muhammad Ali Yousaf⁶, Muhammad Umair⁶ and Rizwan Majeed⁷

¹Department of Unmanned Vehicle Engineering, Sejong University, Seoul, 05006, Korea
²Department of Information Technology, Khwaja Fareed University of Engineering and Information Technology, Rahim Yar Khan, 64200, Pakistan
³School of Computer and Information Technology, Beaconhouse National University, Tarogil, Lahore, 53700, Pakistan
⁴Riphah School of Computing & Innovation, Faculty of Computing, Riphah International University, Lahore Campus, Lahore, 54000, Pakistan
⁵Department of Computer Science, College of Computer Science and Information Technology, Imam Abdulrahman Bin Faisal University, Dammam, 31441, Saudi Arabia
⁶Faculty of Information Technology, University of Central Punjab, Lahore, 54782, Pakistan
⁷Directorate of IT, The Islamia University of Bahawalpur, Bahawalpur, 63100, Pakistan

*Corresponding Author: Muhammad Adnan Khan. Email: adnan.khan@riphah.edu.pk

Received: 30 August 2020; Accepted: 24 December 2020

Abstract: Coronaviruses are a family of viruses that can be transmitted from one person to another. Earlier strains have only been mild viruses, but the current form, known as coronavirus disease 2019 (COVID-19), has become a deadly infection. The outbreak originated in Wuhan, China, and has since spread worldwide. The symptoms of COVID-19 include a dry cough, sore throat, fever, and nasal congestion. Antimicrobial drugs, pathogen–host interaction, and 2 weeks of isolation have been recommended for the treatment of the infection. Safe operating procedures, such as the use of face masks, hand sanitizer, handwashing with soap, and social distancing, are also suggested. Moreover, travel bans for cities, states, and countries have been put in place, along with lockdowns to control the outbreak. Travel restrictions, mask use, sanitizer or soap use, and avoidance of touching the face and nose have produced encouraging results, whereas the effectiveness of antibiotics has not been proved. The results of isolation for the recovery of infected people have also been promising. Travel bans and lockdowns have caused a slump in economies, and unemployment has risen sharply, resulting in an increase in mental health cases globally. To date, vaccines have been developed and are in use in certain countries, but following standard operating procedures remain critical. The countries following the guidelines can eradicate this virus. New Zealand was the first country to eliminate the virus from their territory.

Keywords: Coronavirus; severe acute respiratory syndrome; middle east respiratory syndrome; world health organization

This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1 Introduction

Humans or animals can become ill owing to a large family of viruses, but coronaviruses are particularly deadly. Several coronaviruses can cause mild infections in humans that are related to respiration, such as the common cold, but they can also cause severe diseases, such as SARS and MERS. The most recent form of coronavirus, discovered after its outbreak in Wuhan, China in December 2019, causes coronavirus disease 2019 (COVID-19), an infectious disease [1]. In the early stages of the disease, the symptoms of COVID-19 can be mild, but they can grow exponentially worse. In some cases, people may feel normal and exhibit no symptoms, although they may still have the disease, making it even more dangerous to others [1].

The symptoms of COVID-19 are a dry cough, runny nose, sore throat, diarrhea, fatigue, nasal congestion, fever, and aches and pains, but of these symptoms, dry cough, fatigue, and fever are the most common symptoms [2]. The recovery rate of COVID-19 is around 80%, and numerous patients recover without any form of special treatment [1]. The ratio of infected people who develop breathing difficulties and experience severe illness is about 1 out of 6. Those who become seriously ill typically have underlying medical issues, such as diabetes, heart problems, and high blood pressure [3].

The disease can be spread from one person to another because small droplets from the mouth or nose of an infected person who exhales or coughs may land on surfaces or people in the vicinity. Therefore, individuals can contract this disease by breathing in droplets exhaled by an individual with COVID-19. They can also contract this disease when they touch a contaminated surface and then touch their mouth, nose, or eyes. Considering the severe consequences of exhaling or coughing, it is advised that individuals stay at least 3 ft (1 m) away from an ill person [4].

The main route for the spread of COVID-19 is through respiratory droplets from the cough of an infected person; however, there is a smaller chance of contracting this disease from someone who is infected but is not showing any symptoms of COVID-19 [1]. Moreover, only mild symptoms are experienced by most infected people who are in the early stages of the disease, but there may still be a chance of contracting the disease from someone who feels relatively well [5].

The research based on coronaviruses (particularly the one that causes COVID-19) suggests that the virus can persist on surfaces for a few hours for up to several days, but the duration is uncertain. There are a few factors to consider, including the humidity or temperature of the environment and the type of surface. Using a simple disinfectant is advised to clean the surface and protect oneself and others by killing the virus [6].

Antibiotics work only on bacterial infections and do not work against viruses. Some guidelines to keep safe from this virus include the avoidance of touching the nose, mouth, or eyes, and washing the hands with an alcohol-based liquid or soap and water. Antibiotics should not be used for COVID-19 because no benefit exists from using them. They should only be used for the treatment of bacterial infections as directed by a physician. The usage of some traditional, Western, or home remedies may alleviate the symptoms of COVID-19, but no evidence indicates that any specific antiviral medicine or vaccine can treat or prevent COVID-19 [7]. The use of a face mask can reduce the risk of spreading COVID-19; masks are effective and still allow for communication with an infected person provided that adequate social distance is also maintained.

To diagnose COVID-19, a test must be administered through the upper respiratory tract, which incorporates the nasal cavity directly at the junction of the nose and throat. The tests are thought to be accurate because a high level of viral organisms gathers in the respiratory tract.
The test lasts for a few seconds, and tests are sent to a laboratory for results. Infected people with mild symptoms are also advised to stay isolated for two weeks. These guidelines must be followed even if the patient has previously recovered from COVID-19, as a person can become infected more than once; hence, another wave of the deadly infection can occur [8].

1.1 Effects of COVID-19

Tab. 1 contains data related to the effects of COVID-19 in Pakistan, according to the World Health Organization (WHO). It includes the number of confirmed cases (5496) and deaths (93) as of April 13, 2020 at 2:00 a.m. Central European Summer Time (CEST) [2].

| Confirmed cases | Deaths |
|-----------------|--------|
| 5496            | 93     |

The information in Tab. 2 is related to the effects of COVID-19 globally (207 countries) according to the WHO, which includes the number of confirmed cases (1,776,867), deaths (111,828), and affected countries (207) as of April 13, 2020 at 2:00 a.m. CEST [2].

| Confirmed cases   | Deaths     | Affected countries |
|-------------------|------------|--------------------|
| 1,776,867         | 111,828    | 207                |

Fig. 1 presents the effects of COVID-19 on a geographical basis worldwide according to WHO, and includes a comparison of the confirmed cases in 6 geographical areas: Europe (913,349), the Americas (610,742), the Western Pacific (121,710), the Eastern Mediterranean (102,710), Southeast Asia (17,385), and Africa (10,259), as of April 13, 2020 at 2:00 a.m. CEST [2].

**Figure 1:** Geographical comparison of COVID-19 cases [2]

Tab. 3 contains information related to the amount of money that has been pledged by different countries to fight COVID-19. Pakistan has pledged $600 million, which includes about $15 million for labor workers and about $7.5 million for tax refunds to exports and industry. Another $7.5 million is for small and medium industries and the agricultural sector, and the rest of the money will be spent as required in other fields (especially medicine). Japan has pledged $19 billion, which includes loan support worth 1.1 trillion yen (Japanese currency). Moreover, people
affected by the closing of schools and professionals in the medical field will obtain 430.8 billion yen in aid, and all companies that have been affected by COVID-19 will be able to obtain low-cost loans because 500 billion yen has been allocated for that purpose by the Japanese government. In addition, China has pledged $9.85 billion [3].

Table 3: Money pledged to fight COVID-19 by country [3]

| Country                  | Money allocated to fight COVID-19 ($) |
|--------------------------|--------------------------------------|
| Pakistan                 | $600 million                          |
| Japan                    | $19 billion                           |
| China                    | $16 billion                           |
| The United States        | $1 trillion                           |
| South Korea              | $9.1 billion                          |
| Australia                | $9.85 billion                         |
| The United Kingdom       | $417 billion                          |
| Thailand                 | $12.2 billion                         |
| France                   | $327 billion                          |
| Hong Kong                | $15.5 billion                         |
| Malaysia                 | $4.6 billion                          |
| Italy                    | $27.3 billion                         |
| Germany                  | $600 billion                          |
| Canada                   | $56.8 billion                         |
| Singapore                | $4.4 billion                          |
| Switzerland              | $10.3 billion                         |
| Spain                    | $127.6 billion                        |
| Eastern Europe           | $96.2 billion                         |
| Middle East              | $58.3 billion                         |

The United States (U.S.) has pledged $1 trillion, which includes providing Americans with direct cash payments, financial stability for virus testing, access to free food for people in need, and paid sick leave. South Korea has pledged $9.1 billion, which includes providing help in terms of rent subsidies, leniency in taxation, and necessary support for households, businesses, and the medical profession. The Middle East has pledged $58.3 billion, which includes Bahrain ($11.4 billion), Egypt ($6.4 billion), Saudi Arabia ($13.3 billion), and the United Arab Emirates ($27.2 billion) [3].

Table 4 presents the number of papers found in 3 different databases using the query coronavirus outbreak. These three databases are Science Direct (5614), Google Scholar (2700), and IEEE Xplore (5).

Table 4: Number of papers on the coronavirus outbreak in 3 databases

| Database         | Quantity of papers |
|------------------|--------------------|
| Science direct   | 5614               |
| Google scholar   | 2700               |
| IEEE Xplore      | 5                  |
Fig. 2 presents the influence of COVID-19 on the stock exchange markets of Tokyo (Nikkei), the U.S. (Dow Jones), and London (FTSE) since the start of the outbreak. The statistics are from April 1, 2020, 9:00 am GMT according to Bloomberg. All these stock exchange markets were trending around 0% before the outbreak of COVID-19, but they suffered enormously as the markets fell to −22.2% for Nikkei, −24.1% for the Dow Jones, and −28.8% for FTSE. These trends highlight the enormous economic impact of the pandemic, which has presented a massive challenge globally [4].

![Figure 2: Effect of COVID-19 on stock exchange markets](image)

Fig. 3 presents the influence of COVID-19 on oil prices in the international market since the start of the outbreak in Wuhan, China. The statistics for oil prices are from April 2, 2020, 9:30 am GMT, according to Bloomberg. The oil price (Brent crude in U.S. dollars per barrel) dropped to its lowest since 2002 to 2003 and is still on a downward trajectory. The consequences of COVID-19 at the global level are evident in the current price of oil at $27.25 per barrel. It is expected that the price will keep decreasing. This crisis will hit the economy of several countries hard, so policymakers and world leaders must address it in the coming months. They should
bring change in geopolitics, but for now, saving the U.S. oil industry is the primary objective of Washington [5].

Fig. 4 presents the influence of COVID-19 on unemployment in the U.S. since the outbreak. Currently, more than 6 million Americans have lost their jobs, according to U.S. Bureau of Labor Statistics. This is one of the worst job-loss rates in U.S. history and is expected to become the worst ever as the virus will not end soon [6].

![Figure 4: Effect of COVID-19 on unemployment in the United States][1]

**Figure 4:** Effect of COVID-19 on unemployment in the United States [6]

Fig. 5 illustrates the influence of COVID-19 on economic growth in terms of the gross domestic product (GDP) of different countries according to the growth forecast of the Organization of Economic Co-operation and Development [7]. All countries are expected to decrease in growth in 2020 owing to the pandemic. China will likely suffer most from the virus, decreasing around

![Figure 5: Forecast of the effect of COVID-19 on economic growth (GDP) by country][2]

**Figure 5:** Forecast of the effect of COVID-19 on economic growth (GDP) by country [7]
1.2% in its growth rate from the year 2019 to 2020. The U.S. will likely come in second, losing about 0.5% of its growth rate during the same period. The U.K. and France are projected to lose around 0.7% and 0.5% of their growth rate from the year 2019 to 2020, respectively. Japan, Germany, the European Union, and Italy are projected to lose 0.4%, 0.3%, 0.5%, and 0.5% of their growth rates, respectively. The world growth rate is projected to fall by around 0.5% from 2019 to 2020.

2 Importance and Challenges

The proposed research was based on various groups from different areas of the world, such as China, the U.S., and Europe, to better predict the spread of COVID-19 [8].

Medical professionals who treat COVID-19 patients have been infected and are experiencing mental health issues as they spend most of their time around patients with COVID-19 and work in areas where these patients are treated [9]. Even countries that have zero cases are on alert because there is no telling how fast this virus can spread. According to early estimates, the rate is estimated to be around 14%, but these initial estimates are imprecise [10]. Misinformation about the disease, which has been perpetuated mostly online, has created issues globally. In the first week of January 2020, more than 15 million posts were created on Twitter regarding the disease, with one conspiracy theory being that the Chinese created this deadly virus to advance economic or political goals [11].

Figure 6: Literature taxonomy of COVID-19

Studies have revealed that the average age for COVID-19 patients is 49. The prevalent sex of patients is male (73%), and almost 50% of patients have underlying health issues, such as
diabetes (20%), cardiovascular disease, or hypertension (15%) [12]. Overseas, the Chinese are experiencing racial discrimination owing to the false information that they created this deadly virus in the laboratory, and they are dealing with mental health issues as a result. Moreover, misinformation has negatively affected Chinese tourism, and people are starting to dislike the country, which has damaged their economy [13].

In addition, extensive time is required to conduct experiments and create a vaccine that can treat infected people so that the outbreak can be controlled and lives can be saved. More time is necessary for scientists to conduct the process rigorously, which is one of the main objectives for controlling the outbreak [14].

Fig. 6 presents the literature taxonomy of COVID-19. The 3 most significant parts of COVID-19 are the disease outbreak, its diagnosis, and its prediction. Moreover, COVID-19 outbreak literature includes information about how the virus started and how it is spreading globally, along with the reasons for its spread, so that it can be controlled through enforcing regulations. The diagnosis includes information about how the virus can be detected in a human being by examining the symptoms and how long they take to appear so that the severity of the condition can be determined in an infected person. Coronavirus prediction involves studying the virus and previous similar viruses to estimate how it will behave in the future. Various economic, social, and health challenges are faced and will continue to be faced by people worldwide owing to COVID-19.

3 Coronavirus Outbreak

The authors of 26 papers related to the COVID-19 outbreak are listed in Tab. 5 along with the sources of the data set. If no source was provided, the table uses the term *not mentioned*. The data set was taken from the Chinese Health Commission [15].

### Table 5: Dataset sources and their acquisition methods

| Sr. No | Paper                        | Acquisition method | Data set sources                          |
|--------|------------------------------|--------------------|-------------------------------------------|
| 1      | Layne et al. [8]             | Not given          | Not mentioned                             |
| 2      | Xiang et al. [9]             | Not given          | Not mentioned                             |
| 3      | Thompson [10]                | Online repository  | Health Commission of China                |
| 4      | Hui et al. [11]              | Online repository  | World Health Organization                 |
| 5      | Patel et al. [12]            | Online repository  | National Health Commission of China       |
| 6      | Wen et al. [13]              | Online repository  | World Health Organization                 |
| 7      | Wu et al. [14]               | Online repository  | Center for Disease Control China          |
| 8      | Lai et al. [16]              | Online repository  | World Health Organization                 |
| 9      | Tang et al. [15]             | Online repository  | Chinese Health Commission                 |
| 10     | Xu et al. [17]               | Online repository  | World Health Organization                 |
| 11     | Wang et al. [18]             | Not given          | Not mentioned                             |
| 12     | Mattiuzzi et al. [19]        | Online repository  | World Health Organization                 |
| 13     | Ullah [20]                   | Not given          | Not mentioned                             |
| 14     | Habibzadeh et al. [21]       | Online repository  | World Health Organization                 |
| 15     | Zhao et al. [22]             | Online repository  | World Health Organization                 |
| 16     | Kang et al. [23]             | Online repository  | National Health Commission of China       |
| 17     | Paules et al. [24]           | Online repository  | World Health Organization                 |

(Continued)
Table 5: (Continued)

| Sr. No | Paper | Acquisition method | Data set sources |
|--------|-------|-------------------|-----------------|
| 18     | Zhou et al. [25] | Offline repository | Medical Center for Public Health of Chongqing |
| 19     | Holshue et al. [26] | Online repository | Chinese Health Authorities |
| 20     | Guo et al. [27] | Online repository | World Health Organization and the Chinese Health Commission |
| 21     | Riou and Althaus [28] | Online repository | Chinese Health Commission |
| 22     | Liu et al. [29] | Online repository | World Health Organization |
| 23     | Phelan et al. [30] | Not given | Not mentioned |
| 24     | Xu et al. [31] | Online repository | World Health Organization |
| 25     | Chang et al. [32] | Offline repository | General Hospital of PLA China, College of Medicine about Critical Care and Respiratory |
| 26     | Lai et al. [33] | Online repository | World Health Organization |

The authors of 26 papers related to the COVID-19 outbreak are presented in Tab. 6 along with methods to control the outbreak and the tools or software used to implement the strategies. The outcomes or observations in the papers are also given [28].

Table 6: Overview of papers related to the COVID-19 outbreak

| Authors     | Method                                           | Software/tools for simulation & implementation | Observation/outcome                                                                 |
|-------------|--------------------------------------------------|------------------------------------------------|--------------------------------------------------------------------------------------|
| Layne et al. [8] | Comparison with the Spanish flu pandemic of 1918 | Pathogen–host interaction                       | Bigger data sets are required for better results using tools.                        |
| Xiang et al. [9] | Isolation                                       | Not used                                       | A shortage of training exists, and correct update sharing is required.               |
| Thompson [10] | From symptoms to being hospitalized; time length calculation | Markov chain Monte Carlo (MCMC)                | Extensive supervision can reduce infection spread and severity.                      |
| Hui et al. [11] | Extensive supervision                             | Not used                                       | More than 90% of patients had a fever, and 80% had a dry cough.                    |
| Patel et al. [12] | Regulations for traveling                        | Disease control centers within laboratories     | Symptoms appeared in 2 to 14 days, and patients with weak immune systems were at elevated risk. |
| Wen et al. [13] | Not given                                        | Not used                                       | Chinese people living abroad experience mental health issues owing to false information. |
| Wu et al. [14] | Quarantine, isolation, and social distancing     | Not used                                       | The objective of outbreak control is to gain extra time for vaccine preparation.     |
| Lai et al. [16] | The realization of control measures for infection in clinical ophthalmology | Personal protective equipment                  | Patients should stay away from others for 2 weeks in isolation and retake tests after isolation. |

(Continued)
| Authors               | Method                                      | Software/tools for simulation & implementation | Observation/outcome                                                                 |
|----------------------|---------------------------------------------|-----------------------------------------------|-------------------------------------------------------------------------------------|
| Tang et al. [15]     | Anti-retroviral drugs                       | The model of transmission is dynamic.          | The best measure is persistent self-isolation.                                      |
| Xu et al. [17]       | Isolation of a pathogen of novel type from below the respiratory tract of the patient | Electron transmission microscopy image        | Research work and financial support are needed along with personal awareness.         |
| Wang et al. [18]     | Antimicrobial drugs                         | If the infection is deemed high risk, screening is done. | There are 2 solutions: isolation and nasal swab tests.                              |
| Mattiuzzi et al. [19] | Abnormal computed tomography (CT) chest scans to check the presence of abnormal lesions | Diagnosis tests through real-time polymerase chain reaction assays | Misinformation creates challenges; a policy regarding false information is needed. |
| Ullah [20]           | Traveling and lockdown restrictions         | Not used                                      | Social distancing can mitigate the outbreak.                                        |
| Habibzadeh et al. [21]| Antiviral drugs, such as remdesivir        | CT and X-rays of the chest                    | To counter pathogens, policies are required.                                        |
| Zhao et al. [22]     | Estimation of the maximum likelihood using the serial interval of the infection | The curve of the model of the epidemic growth is exponential. | The number of unreported cases was 469 between January 1–15.                      |
| Kang et al. [23]     | Intervention teams for psychology           | Not used                                      | Mental health problems weaken decision-making by health workers and distract them.   |
| Paules et al. [24]   | The broad scope of antivirals and the procedure for clinical diagnosis | Technology concerning the vaccine messenger ribonucleic acid | The earlier perception of the coronavirus has changed from it being a mild cold. |
| Zhou et al. [25]     | For 28 days, the trials of control and intervention groups were randomly conducted. | Rate of clinical improvement, hospitalization, and duration of mechanical ventilation | The effectiveness of oral and parenteral glucocorticoids was evaluated on patients with the virus. |
| Holshue et al. [26]  | Swab patterns related to nasopharyngeal and test of implications related to nucleic acid | Radiographs of the lateral chest              | To fight this virus, patient information should be shared at all levels.           |
| Guo et al. [27]      | Transcriptomic-meta sequencing             | Ribonucleic acid genomes                      | Vaccine trials are ongoing, as it has spread outside China in 85 regions/countries. |
| Riou et al. [28]     | Virus exposure concerning respiration is compared with the past. | Outbreak trajectories using random simulation | The initial patterns show similarity with SARS (2002).                              |
| Liu et al. [29]      | Encryption algorithm of international data using mean sequential interval lengths | Model of the adjustment in exponential form and decay of mathematical incidence | The virus value was 3.28, and the median was 2.79, and 1.16 was the interquartile range value; these values were higher than the WHO estimation of 1.95. |
| Phelan et al. [30]   | All incoming and outgoing transportation in the city is prohibited, and vehicle traffic is banned during lockdown. | Not used                                      | The late reactions after the virus outbreak cost lives and increased mental health cases. |

(Continued)
Table 6: Continued

| Authors          | Method                        | Software/tools for simulation & implementation | Observation/outcome |
|------------------|-------------------------------|-----------------------------------------------|---------------------|
| Xu et al. [31]   | Statistical analysis          | Confirmation and treatment in laboratories     | The 19–40 age group made up 40% of patients, 53% were 41–65, 3% were 10–11, and 3% were older than 65. |
| Chang et al. [32]| Patients’ throat swabs sent to the disease control center using the polymerase chain reaction procedure | CT or radiography of the chest                  | Thirty-four was the average age of patients, and the male patient ratio was 77%. |
| Lai et al. [33]  | Epidemiology                  | Clinical manifestations                         | Intensive-care units were required for 26% of patients; 20% of patients had acute respiratory distress syndrome. |

4 Coronavirus Diagnosis

The authors of 12 papers related to COVID-19 diagnosis are presented in Tab. 7 along with the sources of the data set. If no source was given in the paper, the table uses the term *not mentioned*. The data set was taken from the Chinese Health Commission [34].

Table 7: Dataset sources and acquisition methods

| Sr. No | Paper                  | Acquisition method     | Data set sources                                      |
|--------|------------------------|------------------------|-------------------------------------------------------|
| 1      | Li et al. [34]         | Online repository       | Chinese Health Commission                             |
| 2      | Shen et al. [35]       | Not given               | Not mentioned                                         |
| 3      | Chen et al. [36]       | Offline repository      | Zhejiang University School of Medicine                |
| 4      | Sabino-Silva et al. [37]| Online repository     | Chinese Center for Disease Control                    |
| 5      | Zhang et al. [38]      | Offline repository      | Central Hospital of Municipal Jinhua                  |
| 6      | Loeffelholz et al. [39]| Online repository       | World Health Organization                             |
| 7      | Shen et al. [40]       | Online repository       | World Health Organization                             |
| 8      | Jin et al. [41]        | Online repository       | Hangzhou Xixi Hospital                                |
| 9      | Li et al. [42]         | Online repository       | World Health Organization                             |
| 10     | Wasserman et al. [43]  | Not given               | Not mentioned                                         |
| 11     | Pasomssub et al. [44]  | Offline repository      | Hospital Ramathibodi of Thailand                     |
| 12     | Moriguchi et al. [45]  | Offline repository      | Japan’s National Institute of Infectious Diseases      |

The authors of 12 papers related to COVID-19 diagnosis are presented in Tab. 8 along with methods to control the outbreak of the pandemic and the tools or software used to implement the methods. Further, the outcomes or observations of the papers are provided. The method for comparison between the results of the two specimens is used along with the implementation of the polymerase chain reaction (PCR) in real-time. As reported, 34.5% of patients were male, and their mean age was 36 [44].
Table 8: Overview of papers related to COVID-19 diagnosis

| Study                | Method                                                                 | Software/tools for simulation & implementation | Observation/outcome                                                                 |
|----------------------|------------------------------------------------------------------------|------------------------------------------------|------------------------------------------------------------------------------------|
| Li et al. [34]       | Patterns of computed tomography (CT) are identified that suggest growth in infection | Examinations of CT scans                        | SARS and COVID-19 have similarities in their CT features. Chest CTs were associated with a low rate of missed diagnosis of COVID-19. |
| Shen et al. [35]     | Antiviral therapy                                                      | Examinations of imaging of chest and laboratory | The infection can also be treated by raising immunity.                                |
| Chen et al. [36]     | Isolation of medical type                                              | Bronchoalveolar lavage and purification of blood | Using an enhanced medical approach, contact between patients and medical personnel can be minimized. |
| Sabino-Silva et al. [37] | The role of aerosols and droplets of saliva in virus transmission    | Oral fluids and procedures of dental clinical   | Saliva contained strains of the virus after 29 days of infection.                   |
| Zhang et al. [38]    | Confirmed 14 cases by the laboratory, analyzed retrospectively         | Detection of acid nucleic and specimens of a pharyngeal swab | No gastrointestinal symptoms were observed in patients with a positive stool test.    |
| Loeffelholz et al. [39] | At the required time, gather specimen from patients               | Bronchoscopy and morbidity                      | For coronavirus and viruses related to the flu, there may be benefits with morbidity. |
| Shen et al. [40]     | Using interferon to treat infected children                           | Imaging of chest and screening                  | Interferon showed no safety or efficacy for treating infected children.             |
| Jin et al. [41]      | Analysis of immunoassay chemiluminescence                             | Test of serological                              | The variance of the titer and the positive rate of IgM was lower than that of IgG in the virus. |
| Li et al. [42]       | Manifestations of clinical type                                        | Technology for identification of immunity and scans of CT | The immune system fights the virus, so the development of the virus is determined by the interaction of the immune system with the virus. |
| Wasserman et al. [43] | The prevalence in point testing to mitigate disease                   | Polymerase chain reaction                       | Symptom development took 3 to 14 days, so testing is favored every 1–2 weeks.       |
| Pasomsub et al. [44] | Comparison between the results of two specimens                       | The polymerase chain reaction in real time      | Male patients represented 34.5% of all patients; their mean age was 36               |
| Moriguchi et al. [45] | Nasopharyngeal CSF and swab                                           | CT scan for chest                                | In serum samples, IgM antibodies and anti-HSV1 were not detected.                   |

5 Coronavirus Prediction

The authors of 3 papers on COVID-19 prediction are presented in Tab. 9 along with the sources of the data set. If no source was given in the specific paper, the table uses the term not mentioned. The data set was taken from a questionnaire survey of Belgium [46].
Table 9: Dataset sources and acquisition methods

| Sr. No | Paper | Acquisition method | Dataset sources |
|--------|-------|--------------------|-----------------|
| 1      | Mertens et al. [46] | Online repository | Questionnaire Survey of Belgium |
| 2      | Yang et al. [47] | Online repository | National Health Commission of China |
| 3      | Ahmadi et al. [48] | Online repository | Ministry of Health Iran |

The authors of 3 papers on COVID-19 prediction documents are presented in Tab. 10 along with methods to control the outbreak and the tools or software used to implement strategies. Moreover, the outcomes or observations of the papers are provided. The integration method of the migration data before and after January 26, 2020 was used with the implementation of the susceptible, exposed, infectious, and removed (SEIR) model because it reports that the trend can be predicted using the SEIR model with rational conviction [47].

Table 10: Overview of papers related to COVID-19 prediction

| Study             | Method                                                                 | Software/tools for simulation & implementation | Observation/outcome |
|-------------------|------------------------------------------------------------------------|-----------------------------------------------|---------------------|
| Mertens et al. [46] | A questionnaire was conducted about the fears of the virus.            | Univariate and simultaneous regression        | The anxiety concerning health was a noted predictor for virus fears. |
| Yang et al. [47]  | Integration of migration data before and after January 26, 2020        | Susceptible, exposed, infectious, removed (SEIR) model | The trend of the epidemic can be predicted by the model of SEIR within the rational conviction. |
| Ahmadi et al. [48] | During specific dates, the projection of the epidemic was determined to predict hospitalized cases | Von Bertalanffy, Gompertz, and error of least squares with the error of the percentage | The epidemic would have flattened from May 13 to July of 2020 in Iran if public health habits had been enforced. |

6 Conclusions

COVID-19 has proved to be a deadly infection that has not only cost lives, but also damaged the economy by forcing businesses into bankruptcy. This has resulted in millions of people becoming unemployed. Mental health cases have also risen, causing an increase in suicides. Countries have taken out loans, and the International Monetary Fund has delayed payments of installments to allocate most of the resources for the fight against the pandemic. To date, vaccines have been developed and are in use in certain countries, but following standard operating procedures remain critical. The countries following the guidelines can eradicate this virus. New Zealand was the first country to eliminate the virus from their territory. The predictions regarding the virus are that it can take up to or more than one year to eradicate it from the world. On the positive side, during this pandemic, several countries have sent medical professionals and equipment to those who are in need. If the world comes together as community, it can fight this deadly virus.

Acknowledgement: We thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of this manuscript.
**Funding Statement:** Authors received no specific funding for the study.

**Conflicts of Interest:** The author declares that he has no conflicts of interest to report regarding the present study.

**References**

[1] 2020. https://www.who.int/news-room/q-a-detail/q-a-coronaviruses.
[2] 2020. https://who.sprinklr.com/.
[3] 2020. https://www.bloomberg.com/news/articles/2020-03-05/here-s-all-the-cash-asian-nations-have-pledged-for-virus-relief.
[4] 2020. https://www.bloomberg.com/markets/stocks.
[5] 2020. https://www.bloomberg.com/markets/commodities.
[6] 2020. https://www.bls.gov/news.release/pdf/empsit.pdf.
[7] 2020. https://data.oecd.org/gdp/real-gdp-forecast.htm.
[8] S. P. Layne, J. M. Hyman, D. M. Morens and J. K. Taubenberger, “New coronavirus outbreak: Framing questions for pandemic prevention,” *Science Translation Medicine*, vol. 12, no. 534, pp. 1–15, 2020.
[9] Y. T. Xiang, Y. Yang, W. Li, L. Zhang, Q. Zhang et al., “Timely mental health care for the 2019 novel coronavirus outbreak is urgently needed,” *Lancet Psychiatry*, vol. 7, no. 3, pp. 228–229, 2020.
[10] R. N. Thompson, “Novel coronavirus outbreak in Wuhan, China, 2020: Intense surveillance is vital for preventing sustained transmission in new locations,” *Journal of Clinical Medicine*, vol. 9, no. 2, pp. 498–504, 2020.
[11] D. S. Hui, I. Azhar, E. Madani, T. A. Ntoumi, F. Kock et al., “The continuing 2019-NCOV epidemic threat of novel coronaviruses to global health—the latest 2019 novel coronavirus outbreak in Wuhan,” *China International Journal of Infectious Diseases*, vol. 91, pp. 264–266, 2020.
[12] A. Patel and D. B. Jernigan, “Initial public health response and interim clinical guidance for the 2019 novel coronavirus outbreak-United States,” *Journal of the American Society of Transplantation and the American Society of Transplant Surgeons*, vol. 20, no. 3, pp. 889–895, 2019.
[13] J. Wen, J. Aston, X. Liu and T. Ying, “Effects of misleading media coverage on public health crisis: A case of the 2019 novel coronavirus outbreak in China,” *An International Journal of Tourism and Hospitality Research*, vol. 31, no. 2, pp. 1–6, 2020.
[14] Z. Wu and J. M. M. Googan, “Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the chinese center for disease control and prevention,” *Journal of American Medical Association*, vol. 323, no. 13, pp. 1–9, 2020.
[15] B. Tang, N. L. Bragazzi, Q. Li, S. Tang, Y. Xiao et al., “An updated estimation of the risk of transmission of the novel coronavirus,” *Infectious Disease Modelling*, vol. 5, pp. 248–255, 2020.
[16] T. H. Lai, E. W. Tang, S. K. Chau, K. S. Fung and K. K. Li, “Stepping up infection control measures in ophthalmology during the novel coronavirus outbreak: An experience from Hong Kong,” *Graefe’s Archive for Clinical and Experimental Ophthalmology*, vol. 258, no. 3, pp. 1–7, 2020.
[17] J. Xu, Y. Chen, H. Chen and B. Cao, “Novel coronavirus outbreak: A quiz or final exam?,” *Frontiers of Medicine*, vol. 14, no. 2, pp. 225–228, 2020.
[18] J. Wang, H. Qi, L. Bao, F. Li and Y. Shi, “A contingency plan for the management of the 2019 novel coronavirus outbreak in neonatal intensive care units,” *Lancet Child and Adolescent Health*, vol. 4, no. 4, pp. 258–259, 2020.
[19] C. Mattiuazzi and G. Lippi, “Which lessons shall we learn from the 2019 novel coronavirus outbreak?,” *Annals of Translational Medicine*, vol. 8, no. 3, pp. 48–56, 2020.
[20] E. Ullah, “The novel coronavirus outbreak: A challenge beyond borders,” *Pakistan Journal of Surgery and Medicine*, vol. 1, no. 1, pp. 8–9, 2020.
[21] P. Habibzadeh and E. K. Stoneman, “The novel coronavirus: A bird’s eye view,” *International Journal of Occupational and Environmental Medicine*, vol. 11, no. 2, pp. 65–74, 2020.
[22] S. Zhao, S. S. Musa, Q. Lin, J. Ran, G. Yang et al., “Estimating the unreported number of novel coronavirus cases in China in the first half of January 2020: A data–driven modelling analysis of the early outbreak,” Journal of Clinical Medicine, vol. 9, no. 2, pp. 388–396, 2020.

[23] L. Kang, Y. Li, S. Hu, M. Chen, C. Yang et al., “The mental health of medical workers in Wuhan, China dealing with the 2019 novel coronavirus,” Lancet Psychiatry, vol. 7, no. 3, pp. 1–14, 2020.

[24] C. I. Paules, H. D. Marston and A. S. Fauci, “Coronavirus infections—more than just the common cold,” Journal of American Medical Association, vol. 323, no. 8, pp. 707–708, 2020.

[25] Y. H. Zhou, Y. Y. Qin, Y. Q. Lu, F. Sun, S. Yang et al., “Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: Protocol of a randomized controlled trial,” Chinese Medical Journal, vol. 10, pp. 1–10, 2020.

[26] M. L. Holshue, C. D. Bolt, S. Lindquist, K. H. Lofy, J. Wiesman et al., “First case of 2019 novel coronavirus in the United States,” New England Journal of Medicine, vol. 382, no. 10, pp. 1–7, 2020.

[27] Y. R. Guo, Q. D. Cao, Z. S. Hong, Y. Y. Tan, S. D. Chen et al., “The origin, transmission and clinical therapies on coronavirus disease 2019 outbreak—an update on the status,” Military Medical Research, vol. 7, no. 1, pp. 1–10, 2020.

[28] J. Riou and C. L. Althaus, “Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus, December 2019 to January 2020,” Europe’s Journal on Infectious Disease Surveillance, Epidemiology, Prevention and Control, vol. 25, no. 4, pp. 2000058–2000067, 2020.

[29] Y. Li and L. Xia, “Coronavirus disease 2019 (COVID-19): Role of chest CT in diagnosis and management,” American Journal of Roentgenology, vol. 214, no. 6, pp. 1280–1286, 2020.

[30] K. Shen, Y. Yang, T. Wang, D. Zhao and Y. Jiang, “Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: Experts’ consensus statement,” World Journal of Pediatrics, vol. 7, pp. 1–9, 2020.

[31] Z. M. Chen, J. F. Fu, Q. Shu, Y. H. Chen, C. Z. Hua et al., “Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus,” World Journal of Pediatrics, vol. 7, pp. 1–7, 2020.
[42] X. Li, M. Geng, Y. Peng, L. Meng and S. Lu, “Molecular immune pathogenesis and diagnosis of COVID-19,” Journal of Pharmaceutical Analysis, vol. 10, no. 2, pp. 102–108, 2020.

[43] M. Wasserman, J. G. Ouslander, A. Lam, A. G. Wolk, J. E. Morley et al., “Diagnostic testing for SARS-coronavirus-2 in the nursing facility: Recommendations of a Delphi panel of long-term care clinicians,” Journal of Nutrition, Health and Aging, vol. 24, no. 20, pp. 1–6, 2020.

[44] E. Pasomsub, S. P. Watcharananan, K. Boonyawat, P. Janchompoo, G. Wongtabtim et al., “Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease-2019 (COVID-19): A cross-sectional study,” Clinical Microbiology and Infection, vol. 2020, pp. 1–14, 2020.

[45] T. Moriguchi, N. Harii, J. Goto, D. Harada, H. Sugawara et al., “A first case of meningitis/encephalitis associated with SARS-coronavirus-2,” International Journal of Infectious Diseases, vol. 94, pp. 55–58, 2020.

[46] G. Mertens, L. Gerritsen, E. Salemink and I. Engelhard, “Fear of the coronavirus (COVID-19): Predictors in an online study conducted in March 2020,” Journal of Anxiety, vol. 20, pp. 1–6, 2020.

[47] Z. Yang, Z. Zeng, K. Wang, S. S. Wong, W. Liang et al., “Modified SEIR and AI prediction of the epidemics trend of COVID-19 in China under public health interventions,” Journal of Thoracic Disease, vol. 12, no. 3, pp. 165–172, 2020.

[48] A. Ahmadi, Y. Fadai, M. Shirani and F. Rahmani, “Modeling and forecasting trend of COVID-19 epidemic in Iran until May 13, 2020,” Medical Journal of the Islamic Republic of Iran, vol. 34, no. 1, pp. 183–195, 2020.